Advertisement

Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations

Published:April 28, 2022DOI:https://doi.org/10.1016/j.clgc.2022.04.014

      Abstract

      The management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly modified by the availability of innovative but expensive treatments, increasing the economic burden of prostate cancer. Here, we aimed to systematically identify and review published economic evaluations (EEs) related to the treatment of mHSPC and assess their quality. A systematic search was performed of the PubMed and Cochrane databases. Three reviewers independently selected EEs by defined inclusion and exclusion criteria. They extracted all data from each EE (general information, study population, data about the EE, interventions and comparators, and outcomes). They also assessed the quality of the selected EEs according to Drummond's checklist. Fourteen EEs published between 2016 and 2021 were eligible for the systematic review. The EEs found ADT + docetaxel to be the most cost-effective of all available treatments as a first-line strategy for mHSPC (abiraterone acetate plus prednisone, enzalutamide, and apalutamide). Five EEs showed that a simple price reduction of abiraterone acetate of 50% to 75% could change the results to render this treatment also cost-effective relative to that with docetaxel. Twelve EEs were of high quality, with a Drummond score ≥ 7. Analysis of the 14 EEs identified by our systematic review, amongst which 78.6% met high quality standards, showed that ADT + docetaxel tends to be the most cost-effective alternative for mHSPC. These results were assessed by sensitivity analysis. The data provided by this systematic review help to provide a better understanding of these treatments and the better use of healthcare resources.

      Keywords

      Abbreviations:

      EE (economic evaluation), mHSPC (metastatic hormone-sensitive prostate cancer), ADT (androgen deprivation therapy), AA (abiraterone acetate plus prednisone), mCRPC (metastatic castration-resistant prostate cancer), ICUR (incremental cost-utility ratio), CUA (cost-utility analysis), WTP (willingness-to-pay), QALY (quality-adjusted life year), LY (life year), CEA (cost-effectiveness analysis)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fitzmaurice C
        • Akinyemiju TF
        • et al.
        • Global Burden of Disease Cancer Collaboration
        Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study.
        JAMA Oncol. 2018; 4: 1553-1568https://doi.org/10.1001/jamaoncol.2018.2706
        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A
        Cancer Statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33https://doi.org/10.3322/caac.21654
        • Weiner AB
        • Nettey OS
        • Morgans AK
        Management of metastatic hormone-sensitive prostate cancer (mHSPC): an evolving treatment paradigm.
        Curr Treat Options Oncol. 2019; 20: 69https://doi.org/10.1007/s11864-019-0668-8
        • Sweeney CJ
        • Chen Y-H
        • Carducci M
        • et al.
        Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
        N Engl J Med. 2015; 373: 737-746https://doi.org/10.1056/NEJMoa1503747
        • James ND
        • Sydes MR
        • Clarke NW
        • et al.
        Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
        Lancet Lond Engl. 2016; 387: 1163-1177https://doi.org/10.1016/S0140-6736(15)01037-5
        • Fizazi K
        • Tran N
        • Fein L
        • et al.
        Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.
        N Engl J Med. 2017; 377: 352-360https://doi.org/10.1056/NEJMoa1704174
        • James ND
        • de Bono JS
        • Spears MR
        • et al.
        Abiraterone for prostate cancer not previously treated with hormone therapy.
        N Engl J Med. 2017; 377: 338-351https://doi.org/10.1056/NEJMoa1702900
        • Davis ID
        • Martin AJ
        • Stockler MR
        • et al.
        Enzalutamide with standard first-line therapy in metastatic prostate cancer.
        N Engl J Med. 2019; 381: 121-131https://doi.org/10.1056/NEJMoa1903835
        • Chi KN
        • Agarwal N
        • Bjartell A
        • et al.
        apalutamide for metastatic, castration-sensitive prostate cancer.
        N Engl J Med. 2019; 381: 13-24https://doi.org/10.1056/NEJMoa1903307
        • Beer TM
        • Armstrong AJ
        • Rathkopf DE
        • et al.
        Enzalutamide in metastatic prostate cancer before chemotherapy.
        N Engl J Med. 2014; 371: 424-433https://doi.org/10.1056/NEJMoa1405095
        • Schnipper LE
        • Davidson NE
        • Wollins DS
        • et al.
        American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options.
        J Clin Oncol Off J Am Soc Clin Oncol. 2015; 33: 2563-2577https://doi.org/10.1200/JCO.2015.61.6706
        • Greenberg D
        • Earle C
        • Fang C-H
        • Eldar-Lissai A
        • Neumann PJ.
        When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.
        J Natl Cancer Inst. 2010; 102: 82-88https://doi.org/10.1093/jnci/djp472
        • Frederix GWJ
        • Severens JL
        • Hövels AM
        • Raaijmakers JAM
        • Schellens JHM
        The cloudy crystal ball of cost-effectiveness studies.
        Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2013; 16: 1100-1102https://doi.org/10.1016/j.jval.2013.06.012
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DG
        • Group PRISMA
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6e1000097https://doi.org/10.1371/journal.pmed.1000097
        • Liberati A
        • Altman DG
        • Tetzlaff J
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        PLOS Med. 2009; 6e1000100https://doi.org/10.1371/journal.pmed.1000100
        • Husereau D
        • Drummond M
        • Petrou S
        • et al.
        Consolidated health economic evaluation reporting standards (CHEERS) statement.
        PharmacoEconomics. 2013; 31: 361-367https://doi.org/10.1007/s40273-013-0032-y
        • Husereau D
        • Drummond M
        • Petrou S
        • et al.
        Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
        Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2013; 16: 231-250https://doi.org/10.1016/j.jval.2013.02.002
        • Board of Governors of the Federal Reserve System
        The Federal Reserve (FED) - Foreign Exchange Rates – G.5A Annual.
        Board of Governors of the Federal Reserve System, 20th Street and Constitution Avenue N.W., Washington, DC 20552020 (Available at:) (Accessed May 18, 2022)
        • Drummond MF
        • Sculpher MJ
        • Claxton K
        • Stoddart GL
        • Torrance GW
        Methods for the Economic Evaluation of Health Care Programmes.
        Oxford University Press, Great Clarendon Street, Oxford, United Kingdom2015
        • Hu X
        • Qu S
        • Yao X
        • Li C
        • Liu Y
        • Wang J
        Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis.
        Cost Eff Resour Alloc CE. 2019; 17: 27https://doi.org/10.1186/s12962-019-0193-4
        • Sathianathen NJ
        • Alarid-Escudero F
        • Kuntz KM
        • et al.
        A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer.
        Eur Urol Oncol. 2019; 2: 649-655https://doi.org/10.1016/j.euo.2019.01.004
      1. Chiang CL, So TH, Lam TC, Choi HCW Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective. Prostate Cancer Prostatic Dis. 2020;23:108-115. doi:10.1038/s41391-019-0161-2

        • Beca J
        • Majeed H
        • Chan KKW
        • Hotte SJ
        • Loblaw A
        • Hoch JS
        Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer.
        Can Urol Assoc J J Assoc Urol Can. 2019; (Published online): 396-403https://doi.org/10.5489/cuaj.5889
        • Aguiar PN
        • Barreto CMN
        • Gutierres B de S
        • Tadokoro H
        • Lopes G de L
        Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.
        Einstein Sao Paulo Braz. 2017; 15: 349-354https://doi.org/10.1590/S1679-45082017GS4017
        • Aguiar PN
        • Tan PS
        • Simko S
        • et al.
        Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
        Einstein Sao Paulo Braz. 2019; 17: eGS4414https://doi.org/10.31744/einstein_journal/2019GS4414
        • Zheng HR
        • Wen F
        • Wu YF
        • Wheeler JRC
        • Li Q
        Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
        Eur J Cancer Care (Engl). 2017; 26https://doi.org/10.1111/ecc.12505
        • Hird AE
        • Magee DE
        • Cheung DC
        • Matta R
        • Kulkarni GS
        • Nam RK
        Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: a microsimulation model.
        Can Urol Assoc J J Assoc Urol Can. 2020; 14: E418-E427https://doi.org/10.5489/cuaj.6234
        • Zhang P
        • Wen F
        • Fu P
        • Yang Y
        • Li Q
        Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
        Tumori. 2017; 103: 380-386https://doi.org/10.5301/tj.5000583
        • Ramamurthy C
        • Handorf EA
        • Correa AF
        • Beck JR
        • Geynisman DM
        Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
        Urol Oncol. 2019; 37: 688-695https://doi.org/10.1016/j.urolonc.2019.05.017
        • Woods BS
        • Sideris E
        • Sydes MR
        • et al.
        Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness.
        Eur Urol Oncol. 2018; 1: 449-458https://doi.org/10.1016/j.euo.2018.06.004
        • Liu M
        • Qu S
        • Liu Y
        • Yao X
        • Jiang W.
        Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
        J Comp Eff Res. 2019; 8: 865-877https://doi.org/10.2217/cer-2018-0133
        • Zhang P-F
        • Xie D
        • Li Q
        Adding enzalutamide to first-line treatment for metastatic hormone-sensitive prostate cancer: a cost-effectiveness analysis.
        Front Public Health. 2021; 9608375https://doi.org/10.3389/fpubh.2021.608375
        • Sung WWY
        • Choi HCW
        • Luk PHY
        • So TH
        A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer.
        Front Oncol. 2021; 11627083https://doi.org/10.3389/fonc.2021.627083
        • Szmulewitz RZ
        • Peer CJ
        • Ibraheem A
        • et al.
        Prospective International Randomized Phase II Study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer.
        J Clin Oncol Off J Am Soc Clin Oncol. 2018; 36: 1389-1395https://doi.org/10.1200/JCO.2017.76.4381
      2. Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH.ca. 2020. Available at: https://www.cadth.ca/fr. Accessed May 18, 2022

      3. The National Institute for Health and Care Excellence (NICE). NICE. 2020. Available at: https://www.nice.org.uk. Accessed May 18, 2022

      4. Department of Economics and Public Health Assessment. Choices in methods for economic evaluation. Published online 2012. Available at: https://www.has-sante.fr/portail/jcms/r_1499251/en/choices-in-methods-for-economic-evaluation?portal=r_1482172&userLang=en. Accessed May 18, 2022.

      5. Health Information Center on Health Service Research and Health Care Technology (NICHSR). Health economics information resources: a self-study course: module 4. 2020. Available at: https://www.nlm.nih.gov/nichsr/edu/healthecon/drummond_list.html. Accessed May 18, 2022

        • Pilon D
        • Queener M
        • Lefebvre P
        • Ellis LA
        Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
        J Med Econ. 2016; 19: 777-784https://doi.org/10.3111/13696998.2016.1173042
        • Barqawi YK
        • Borrego ME
        • Roberts MH
        • Abraham I
        Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
        J Med Econ. 2019; 22: 1202-1209https://doi.org/10.1080/13696998.2019.1661581
        • Kreis K
        • Horenkamp-Sonntag D
        • Schneider U
        • Zeidler J
        • Glaeske G
        • Weissbach L
        Treatment-related healthcare costs of metastatic castration-resistant prostate cancer in germany: a claims data study.
        PharmacoEconomics - Open. 2020; (Published online)https://doi.org/10.1007/s41669-020-00219-6
        • Kearns B
        • Pandor A
        • Stevenson M
        • et al.
        Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen: an evidence review group perspective of a NICE single technology appraisal.
        PharmacoEconomics. 2017; 35: 415-424https://doi.org/10.1007/s40273-016-0457-1
        • Flannery K
        • Drea E
        • Hudspeth L
        • et al.
        Budgetary impact of cabazitaxel use after docetaxel treatment for metastatic castration-resistant prostate cancer.
        J Manag Care Spec Pharm. 2017; 23: 416-426https://doi.org/10.18553/jmcp.2017.23.4.416
        • Pelloux-Prayer R
        • Schiele P
        • Oudard S
        • et al.
        Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer.
        Clin Genitourin Cancer. 2021; (Published online)https://doi.org/10.1016/j.clgc.2021.03.022
        • Armstrong AJ
        • Szmulewitz RZ
        • Petrylak DP
        • et al.
        ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.
        J Clin Oncol Off J Am Soc Clin Oncol. 2019; 37: 2974-2986https://doi.org/10.1200/JCO.19.00799
        • Fizazi K
        • Maldonado X
        • Foulon S
        • Roubeau G
        A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): first results of PEACE-1.
        J Clin Oncol. 2021; 39 (suppl 15; abstr 5000). In: 2021 ASCO Annual Meetinghttps://doi.org/10.1200/JCO.2021.39.15_suppl.5000
        • Bayer
        A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer.
        clinicaltrials.gov, National Library of Medicine 8600 Rockville Pike Bethesda, MD 208942021 (Available at:) (Accessed May 18, 2022)